Schizophrenia 6 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

SCZD6 MCID: SCH081 MIFTS: 27	Schizophrenia 6 (SCZD6) Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Schizophrenia 6

MalaCards integrated aliases for Schizophrenia 6:

Name: Schizophrenia 6 ⁵⁷ ¹² ²⁹ ⁷²

Schizophrenia Susceptibility Locus, Chromosome 8p-Related ⁵⁷ ¹³

Sczd6 ⁵⁷ ¹²

Schizophrenia, Type 6 ⁴⁰

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Mental diseases Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0070082

OMIM ⁵⁷ 603013

MedGen ⁴² C1864275

UMLS ⁷² C1864275

Sources

Summaries for Schizophrenia 6

Disease Ontology : ¹² A schizophrenia that has material basis in an autosomal dominant mutation of SCZD6 on chromosome 8p21.

MalaCards based summary : Schizophrenia 6, also known as schizophrenia susceptibility locus, chromosome 8p-related, is related to schizophrenia and myocardial infarction. An important gene associated with Schizophrenia 6 is NRG1 (Neuregulin 1). The drugs Tranquilizing Agents and Antidepressive Agents have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes.

More information from OMIM: 603013

Sources

Related Diseases for Schizophrenia 6

Diseases in the Schizophrenia family:

Schizophrenia 1	Schizophrenia 3
Schizophrenia 4	Schizophrenia 6
Schizophrenia 5	Schizophrenia 7
Schizophrenia 8	Schizophrenia 2
Schizophrenia 9	Schizophrenia 10
Schizophrenia 11	Schizophrenia 12
Schizophrenia 14	Schizophrenia 13
Schizophrenia 15	Schizophrenia 16
Schizophrenia 18	Schizophrenia 19
Early-Onset Schizophrenia

Diseases related to Schizophrenia 6 via text searches within MalaCards or GeneCards Suite gene sharing:

#	Related Disease	Score	Top Affiliating Genes
1	schizophrenia	28.6	SCZD6 NRG1
2	myocardial infarction	9.7
3	acute myocardial infarction	9.7

Sources

Symptoms & Phenotypes for Schizophrenia 6

Clinical features from OMIM:

603013

Sources

Drugs & Therapeutics for Schizophrenia 6

Drugs for Schizophrenia 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Tranquilizing Agents

Phase 3

Antidepressive Agents

Phase 3

Quetiapine Fumarate

Phase 3

111974-72-2

Central Nervous System Depressants

Phase 3

Antipsychotic Agents

Phase 3

Psychotropic Drugs

Phase 3

Oxytocin

Approved, Vet_approved

Phase 2

50-56-6

439302 53477758

Synonyms:

(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide

(Arg8)-vasopressin

(Arg8)-vasotocin

1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide

50-56-6

AC1L9735

alpha-Hypophamine

Argipressin

Argpressin acetate

BCBcMAP01_000094

Biotinyl-(arg8)-vasopressin

C00746

CHEBI:492195

CHEBI:7872

CHEMBL395429

CID439302

Cys-tyr-ile-GLN-asn-cys-pro-arg-gly-NH2

Cys-tyr-ile-GLN-asn-cys-pro-leu-gly-NH2

Cys-tyr-ile-THR-asn-cys-gly-leu-gly-NH2

Cys-tyr-phe-GLN-asn-cys-pro-arg-gly-NH2

Cys-tyr-phe-GLN-asn-cys-pro-lys-gly-NH2

D00089

Disulfide bridge cys1-cys6

Gly-leu-pro-c

HS-2021

L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide

MolPort-003-938-941

NCGC00167132-01

nchembio.184-comp2

O3251_SIGMA

O4375_SIGMA

Ocytocin

Oxitocina

OXT

Oxytocic hormone

Oxytocin

OXYTOCIN

Oxytocin (JP15/USP/INN)

Oxytocin (TN)

Oxytocin 10 usp units in dextrose 5%

Oxytocin 20 usp units in dextrose 5%

Oxytocin 5 usp units in dextrose 5%

Oxytocin acetate

Oxytocin injection

Oxytocine

Oxytocinum

Pitocin

Pitocin (TN)

Syntocinon

Syntocinon (TN)

TI-001

Olanzapine

Approved, Investigational

Phase 2

132539-06-1

4585

Synonyms:

132539-06-1

2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine

2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine

2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine

2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine

2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine

2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine

2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine

AC1L1IHS

AC-665

AKOS000282888

ALKS-7921

BIDD:GT0332

BIDD:PXR0138

Bio-0169

C07322

C076029

C17H20N4S

CHEBI:7735

CHEMBL715

CID4585

CPD000466345

D00454

DB00334

Eli Lilly brand of olanzapine

HMS2051H05

HMS2089M04

HMS2093I04

I06-0784

InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H

InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

Jsp001969

KS-1090

L000455

L005958

Lanzac

Lilly brand of olanzapine

LS-152313

LY 170053

LY-170052

LY-170053

Midax

MLS000759457

MLS001165781

MLS001195646

MLS001424057

MolPort-002-885-845

MolPort-003-666-569

MolPort-005-977-341

NCGC00096077-01

NCGC00096077-03

NCGC00096077-04

Olansek

Olanzapin

olanzapina

Olanzapina

olanzapine

Olanzapine

Olanzapine (JAN/USAN/INN)

Olanzapine (OLA)

Olanzapine [USAN:INN]

olanzapinum

Olanzapinum

S2493_Selleck

SAM001246652

SMR000466345

SPECTRUM1505024

STK634338

Symbyax

TL8000772

UNII-N7U69T4SZR

Zalasta

Zydis

Zyprexa

Zyprexa (TN)

Zyprexa intramuscular

Zyprexa Intramuscular

Zyprexa Velotab

Zyprexa zydis

Zyprexa Zydis

Rimonabant

Approved, Investigational

Phase 2

158681-13-1, 168273-06-1

104850

Synonyms:

[3H]SR141716A

168273-06-1

5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide

5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide

5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide

5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide

A 281

AC-163720

AC1L2XM5

AC-731

Acomplia

Acomplia (TN)

C14319

CHEMBL111

CID104850

D05731

DB06155

I06-0381

L000572

LS-128155

MolPort-003-850-185

N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride

NCGC00164572-01

nchembio.129-comp21

nchembio.552-comp16

Rimonabant

Rimonabant (JAN/USAN/INN)

Rimonabant [USAN:INN]

Rimoslim

Riobant

Slimona

SR 141716

SR 141716a

SR141,716A

SR141716

SR-141716

SR141716a

SR141716A

SR-141716A

STK642500

UNII-RML78EN3XE

Zimulti

ZINC01540228

Serine

Approved, Nutraceutical

Phase 2

56-45-1

5951

Synonyms:

(-)-Serine

(2S)-2-amino-3-Hydroxypropanoate

(2S)-2-amino-3-Hydroxypropanoic acid

(S)-(-)-Serine

(S)-2-amino-3-Hydroxypropanoate

(S)-2-amino-3-Hydroxy-propanoate

(S)-2-amino-3-Hydroxypropanoic acid

(S)-2-amino-3-Hydroxy-propanoic acid

(S)-2-Amino-3-hydroxypropanoic acid

(S)-a-amino-b-Hydroxypropionate

(S)-a-amino-b-Hydroxypropionic acid

(S)-alpha-amino-beta-Hydroxypropionate

(S)-alpha-amino-beta-Hydroxypropionic acid

(S)-b-amino-3-Hydroxypropionate

(S)-b-amino-3-Hydroxypropionic acid

(S)-beta-amino-3-Hydroxypropionate

(S)-beta-amino-3-Hydroxypropionic acid

(S)-Serine

(S)-α-amino-β-hydroxypropionate

(S)-α-amino-β-hydroxypropionic acid

2-amino-3-Hydroxypropanoate

2-amino-3-Hydroxypropanoic acid

3-Hydroxy-L-alanine

alpha-Amino-beta-hydroxypropionic acid

beta-Hydroxyalanine

beta-Hydroxy-L-alanine

b-Hydroxyalanine

b-Hydroxy-L-alanine

L Serine

L-(-)-Serine

L-2-amino-3-Hydroxypropionate

L-2-amino-3-Hydroxypropionic acid

L-3-Hydroxy-2-aminopropionate

L-3-Hydroxy-2-aminopropionic acid

L-3-Hydroxy-alanine

L-Ser

L-Serin

L-Serine

Ser

Serina

Serine

SERINE

Serinum

β-hydroxyalanine

β-hydroxy-L-alanine

Oxytocics

Phase 2

Serotonin Agents

Phase 2

Serotonin Uptake Inhibitors

Phase 2

Antiemetics

Phase 2

Gastrointestinal Agents

Phase 2

Peripheral Nervous System Agents

Phase 2

Neurotransmitter Uptake Inhibitors

Phase 2

Autonomic Agents

Phase 2

Neurotransmitter Agents

Phase 2

Hormone Antagonists

Phase 2

Hormones

Phase 2

Anti-Obesity Agents

Phase 2

Cannabinoid Receptor Antagonists

Phase 2

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 2

Serotonin

Investigational, Nutraceutical

Phase 2

50-67-9

5202

Synonyms:

3-(2-Aminoethyl)-1H-indol-5-ol

3-(2-Aminoethyl)indol-5-ol

3-(b-Aminoethyl)-5-hydroxyindole

5 Hydroxytryptamine

5-HT

5-HTA

5-Hydroxy-3-(b-aminoethyl)indole

5-Hydroxyltryptamine

5-Hydroxytriptamine

5-Hydroxytryptamine

5-Hydroxy-tryptamine

Antemovis

DS Substance

Enteramin

Enteramine

Hippophaine

Hydroxytryptamine

Serotonine

sérotonine

thrombocytin

Thrombocytin

thrombotonin

Thrombotonin

Dopamine

Approved

51-61-6, 62-31-7

681

Synonyms:

(3H)-Dopamine

.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane

.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride

1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)

1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride

1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium

153C5321-5FEE-4B0B-8925-F388F0EEEBD1

2-(3,4-dihydroxyphenyl)ethylamine

2-(3,4-Dihydroxyphenyl)ethylamine

2-benzenediol

3,4 Dihydroxyphenethylamine

3,4-dihydroxyphenethylamine

3,4-Dihydroxyphenethylamine

3,4-Dihydroxyphenethylamine hydrochloride

3,4-Dihydroxyphenylethylamine

3-Hydroxtyramine

3-Hydroxytyramine

3-Hydroxytyramine Hydrobromide

3-Hydroxytyramine hydrochloride

4-(2-Aminoethyl)-1,

4-(2-aminoethyl)-1,2-benzenediol

4-(2-Aminoethyl)-1,2-benzenediol

4-(2-Aminoethyl)-1,2-bezenediol

4-(2-Aminoethyl)benzene-1,2-diol

4-(2-aminoethyl)catechol

4-(2-Aminoethyl)catechol

4-(2-aminoethyl)pyrocatechol

4-(2-aminoethyl)-pyrocatechol

4-(2-Aminoethyl)pyrocatechol

4-(2-Aminoethyl)-pyrocatechol

4-(2-Aminoethyl)pyrocatechol hydrochloride

50444-17-2

51-61-6

62-31-7 (HYDROCHLORIDE)

a-(3,4-Dihydroxyphenyl)-b-aminoethane

AC1L19S5

AC1Q54AX

AC1Q54AY

AKOS003790978

alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane

ASL 279

BIDD:ER0506

Biomol-NT_000001

BPBio1_001123

BSPBio_001932

C03758

CHEBI:18243

CHEMBL59

CID681

cMAP_000036

cMAP_000065

D07870

DB00988

Deoxyepinephrine

DivK1c_000780

Dopamin

Dopamina

Dopamina [INN-Spanish]

dopamine

Dopamine

Dopamine (INN)

Dopamine (USAN)(*hydrochloride*)

Dopamine [INN:BAN]

Dopamine hydrochloride

Dopaminum

Dopaminum [INN-Latin]

Dopastat

Dophamine

Dynatra

EINECS 200-110-0

HSDB 3068

Hydrochloride, dopamine

Hydroxytyramin

hydroxytyramine

Hydroxytyramine

IDI1_000780

intropin

Intropin

Intropin [*hydrochloride*]

IP 498

KBio1_000780

KBio2_001492

KBio2_002388

KBio2_002484

KBio2_004060

KBio2_004956

KBio2_005052

KBio2_006628

KBio2_007524

KBio2_007620

KBio3_001152

KBio3_002867

KBio3_002962

KBioGR_001129

KBioGR_002388

KBioGR_002484

KBioSS_001492

KBioSS_002393

KBioSS_002491

KW-3-060

L000232

L-DOPAMINE

LDP

Lopac0_000586

Lopac-H-8502

LS-159

Medopa (TN)

m-Hydroxytyramine hydrochloride

MolPort-001-641-000

NCGC00015519-01

NCGC00015519-08

NCGC00096050-01

NCGC00096050-02

NCGC00096050-03

NCGC00096050-04

NCGC00096050-05

nchembio.105-comp9

nchembio.107-comp4

nchembio.284-comp1

nchembio.78-comp16

nchembio.89-comp3

nchembio705-8

nchembio801-comp8

NINDS_000780

NSC 173182

NSC169105

NSC173182

Oprea1_088821

Oxytyramine

Pyrocatechol, 4-(2-aminoethyl)- (8CI)

Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride

Revimine

Revivan

SPBio_001205

Spectrum_001012

SPECTRUM1505155

Spectrum2_001023

Spectrum3_000406

Spectrum4_000525

Spectrum5_000945

ST048774

STK301601

UNII-VTD58H1Z2X

UPCMLD0ENAT5885989:001

Dopamine Agents

Serotonin 5-HT2 Receptor Antagonists

Serotonin Antagonists

Paliperidone Palmitate

Dopamine Antagonists

Dopamine D2 Receptor Antagonists

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated)	Completed	NCT00206128	Phase 3	Seroquel SR
2	A Randomized Trial Administering Oxytocin vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia and Schizo-affective Disorder	Unknown status	NCT01598623	Phase 2	Oxytocin
3	D-serine Antipsychotic Monotherapy for Treatment Refractory Schizophrenia	Completed	NCT00816894	Phase 2	D-serine;Olanzapine
4	The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia	Terminated	NCT00547118	Phase 2	Rimonabant;Placebo
5	Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan	Unknown status	NCT01357005
6	Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan	Unknown status	NCT01249079
7	Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan	Unknown status	NCT01077687
8	INVega Is Studied In an Observational Design in the Netherlands	Completed	NCT00697658		Paliperidone ER
9	The Effectiveness of The Meta-cognitive Training Among Chronic Schizophrenia Patients Treated Within Community Support Groups in Poland.	Completed	NCT02187692
10	Cognitive Remediation Program for Hospitalized in the Long Term Patients With Deficit Schizophrenia : Impact on the Capacities of Autonomy	Not yet recruiting	NCT03407950

Search NIH Clinical Center for Schizophrenia 6

Sources

Genetic Tests for Schizophrenia 6

Genetic tests related to Schizophrenia 6:

#	Genetic test	Affiliating Genes
1	Schizophrenia 6 ²⁹	NRG1

Sources

Anatomical Context for Schizophrenia 6

MalaCards organs/tissues related to Schizophrenia 6:

⁴¹

Brain, Cortex, Testes, Prefrontal Cortex

Sources

Publications for Schizophrenia 6

Articles related to Schizophrenia 6:

(show top 50) (show all 52)

#	Title	Authors	PMID	Year
1	Extreme population differences across Neuregulin 1 gene, with implications for association studies. ⁸	Gardner M...Comas D	16189508	2006
2	No evidence for linkage or association of neuregulin-1 (NRG1) with disease in the Irish study of high-density schizophrenia families (ISHDSF). ⁸	Thiselton DL...Kendler KS	15197397	2004
3	Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. ⁸	Li T...Collier DA	15007393	2004
4	No association with the neuregulin 1 haplotype to Japanese schizophrenia. ⁸	Iwata N...Ozaki N	14699424	2004
5	Polymorphisms within 5' end of the Neuregulin 1 gene are genetically associated with schizophrenia in the Chinese population. ⁸	Tang JX...He L	14647391	2004
6	Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. ⁸	Miyakawa T...Tonegawa S	12851457	2003
7	Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. ⁸	Gerber DJ...Tonegawa S	12851458	2003
8	Neuregulin 1 and susceptibility to schizophrenia. ⁸	Stefansson H...Stefansson K	12145742	2002
9	Genetic association studies of schizophrenia using the 8p21-22 genes: prepronociceptin (PNOC), neuronal nicotinic cholinergic receptor alpha polypeptide 2 (CHRNA2) and arylamine N-acetyltransferase 1 (NAT1). ⁸	Blaveri E...Gurling HM	11436130	2001
10	Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. ⁸	Blouin JL...Pulver AE	9731535	1998
11	NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. ⁸	Kaufmann CA...Cloninger CR	9674972	1998
12	Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families. ⁸	Kendler KS...Straub RE	8942448	1996
13	The Johns Hopkins University Collaborative Schizophrenia Study: an epidemiologic-genetic approach to test the heterogeneity hypothesis and identify schizophrenia susceptibility genes. ⁸	Pulver AE...Kempf L	9246505	1996
14	Clinical staging in severe mental disorders; bipolar disorder, depression and schizophrenia. ³⁸	de la Fuente-Tomas L...Bobes J	30314812	2019
15	Schizophrenia is a later-onset feature of PCDH19 Girls Clustering Epilepsy. ³⁸	Vlaskamp DRM...Andrade DM	30828795	2019
16	A randomized controlled trial of a mindfulness-based intervention program for people with schizophrenia: 6-month follow-up. ³⁸	Wang LQ...Karatzias T	27994466	2016
17	Monitoring of physical health parameters for inpatients on a child and adolescent mental health unit receiving regular antipsychotic therapy. ³⁸	Pasha N...Drewek K	26734455	2015
18	Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study. ³⁸	Nordon C...Falissard B	23600715	2014
19	A modified Drug Attitude Inventory used in long-term patients in sheltered housing. ³⁸	Stjernsward S...Levander S	23265955	2013
20	Burden of disease in adolescents and young people in Spain. ³⁸	Catala-Lopez F...Morant-Ginestar C	23084798	2013
21	Early-onset schizophrenia. ³⁸	Remschmidt H...Theisen F	22797279	2012
22	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. ³⁸	Fraguas D...Arango C	20702068	2011
23	MMPI-II personality profiles of patients with psychogenic nonepileptic seizures. ³⁸	Bodde NM...Boon PA	21450531	2011
24	Follow-up of subjects with suspected pre-psychotic state in Taiwan. ³⁸	Liu CC...Hwu HG	21112187	2011
25	[Clinical-genetic parameters and the nosological evaluation of schizoaffective psychosis in systematics of attack-like endogenous psychoses]. ³⁸	Panteleeva GP...Shchekal KE	21512496	2011
26	Diffusion tensor anisotropy in the cingulate gyrus in schizophrenia. ³⁸	Segal D...Hof PR	20045072	2010
27	Increased risk of acute myocardial infarction after acute episode of schizophrenia: 6 year follow-up study. ³⁸	Lin HC...Lin HC	20050720	2010
28	Increased cortical inhibition in persons with schizophrenia treated with clozapine. ³⁸	Daskalakis ZJ...Chen R	18308816	2008
29	GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for alpha5 subunit. ³⁸	Asai Y...Suhara T	18042347	2008
30	Urticaria and angio-oedema due to ziprasidone. ³⁸	Akkaya C...Kirli S	17446198	2007
31	Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance. ³⁸	Bell M...Bryson G	17943687	2007
32	Dysfunction of dorsolateral prefrontal cortex in antipsychotic-naïve schizophreniform psychosis. ³⁸	Harrison BJ...Pantelis C	17052898	2006
33	Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. ³⁸	Cannon TD...Peltonen L	16275808	2005
34	Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study. ³⁸	Soyka M...Tatsch K	15834758	2005
35	Longitudinal course of schizophrenia spectrum symptoms in offspring of psychiatrically hospitalized mothers. ³⁸	Carlson GA...Fish B	16092904	2005
36	Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. ³⁸	Haro JM...SOHO advisory board	15701107	2005
37	[Distribution of latencies of visual evoked potentials in a sample of schizophrenic patients]. ³⁸	Malyszczak K...Sobieszczanska M	14727371	2003
38	A cluster-analytic investigation of MMPI profiles of serious male and female juvenile offenders. ³⁸	Espelage DL...Steiner H	12819436	2003
39	Mental illness and menopause: a patient and family perspective. ³⁸	Sajatovic M...Bingham CR	12814000	2003
40	Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. ³⁸	Segman RH...Lerer B	11317227	2001
41	[Morphometric study of ultrastructural changes in oligodendroglial cells in the postmortem brain in endogenous psychoses]. ³⁸	Uranova NA...Rakhmanova VI	11523429	2001
42	The carbohydrate deposits detected by histochemical methods in the molecular layer of the dentate gyrus in the hippocampal formation of patients with schizophrenia, Down's syndrome and dementia, and aged person. ³⁸	Nishimura A...Nishi K	11443283	2000
43	Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. ³⁸	Cole JO...Kando JC	8262890	1993
44	Auditory P300 studies in schizophrenic subjects and their first degree relatives. ³⁸	Black JL...De Roach JN	1642573	1992
45	[Review of the concept of personality deterioration in schizophrenia]. ³⁸	Donnoli VF	1862715	1991
46	[Suicidal tendencies in endogenous and organic depression in elderly patients]. ³⁸	Shamiev RKh	3232462	1988
47	Sialic acid in platelets of schizophrenic patients. ³⁸	Sirota P...Levinsky H	3363163	1988
48	Drug-induced growth hormone and prolactin responses in schizophrenia research. ³⁸	Lal S...Guyda H	6131495	1982
49	Efficacy of loxapine in the treatment of paranoid schizophrenia. ³⁸	Bishop MP...Kiltie H	14350	1977
50	[Clinico-epidemiologic study of the mental state of a group of elderly persons from the general population]. ³⁸	Gavrilova SI	919967	1977

Sources

Genes for Schizophrenia 6

Genes related to Schizophrenia 6 (2 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	NRG1	Neuregulin 1	Protein Coding	100	Genetic Tests ²⁹
2	SCZD6	Schizophrenia Disorder 6	Genetic Locus	50	Genetic linkage ⁵⁷ Susceptibility factor ⁵⁷

Sources

Variations for Schizophrenia 6

Sources

Expression for Schizophrenia 6

Search GEO for disease gene expression data for Schizophrenia 6.

Sources

Pathways for Schizophrenia 6

Sources

GO Terms for Schizophrenia 6

Sources

Sources for Schizophrenia 6

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia

Schizophrenia 6 (SCZD6)

Aliases & Classifications for Schizophrenia 6

MalaCards integrated aliases for Schizophrenia 6:

Classifications:

External Ids:

Summaries for Schizophrenia 6

Related Diseases for Schizophrenia 6

Diseases in the Schizophrenia family:

Diseases related to Schizophrenia 6 via text searches within MalaCards or GeneCards Suite gene sharing:

Symptoms & Phenotypes for Schizophrenia 6

Clinical features from OMIM:

Drugs & Therapeutics for Schizophrenia 6

Drugs for Schizophrenia 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Schizophrenia 6

Genetic tests related to Schizophrenia 6:

Anatomical Context for Schizophrenia 6

MalaCards organs/tissues related to Schizophrenia 6:

Publications for Schizophrenia 6

Articles related to Schizophrenia 6:

Genes for Schizophrenia 6

Genes related to Schizophrenia 6 (2 elite genes):

Variations for Schizophrenia 6

Expression for Schizophrenia 6

Pathways for Schizophrenia 6

GO Terms for Schizophrenia 6

Sources for Schizophrenia 6